Austin, TXNCT06703489Now EnrollingIRB Ready

Ventricular Tachycardia (VT) Clinical Trial in Austin, TX

Access cutting-edge ventricular tachycardia (vt) treatment through this clinical trial at a research site in Austin. Study-provided care at no cost to qualified participants.

Sponsored by Medtronic Cardiac Ablation Solutions

Quick Self-Assessment

See if you qualify for this Austin location

Preparing your pre-screening questions…

Expert Care in Austin

Access ventricular tachycardia (vt) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ventricular tachycardia (vt) treatment provided free

Apply for This Austin Location

Check if you qualify for this ventricular tachycardia (vt) clinical trial in Austin, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Austin

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Austin site if eligible
  4. 4Begin participation

About This Ventricular Tachycardia (VT) Study in Austin

Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.

Sponsor: Medtronic Cardiac Ablation Solutions

Who Can Participate

Inclusion Criteria

Any of the following:
Ischemic cardiomyopathy (ICM) patients with prior history of myocardial infarction (MI).
Non-ischemic cardiomyopathy (NICM) patients with documented myocardial scar in a territory without coronary stenosis as evidenced by cardiac imaging.
At least one episode of sustained (continuous for \>30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.
Recurrence of sustained ventricular tachycardia despite class I or III antiarrhythmic drug therapy or ICD intervention.
Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 3 months prior to the ablation procedure.
Age 18 through 85 years old.
Willing and able to provide informed consent.
Willing and able to comply with all pre-, post-, and follow-up testing requirements.

Exclusion Criteria

Incessant VT necessitating hemodynamic support prior to the ablation procedure.
Unstable polymorphic VT or ventricular fibrillation (VF).
VTs due to any of the following:
Idiopathic VT
Automaticity or triggered activity
Lamin or titin genetic mutation
Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug induced arrhythmia).
NICM subjects with active inflammatory processes (e.g., myocarditis) within 120 days prior to the ablation procedure.
VT or VF thought to be from channelopathies.
More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.
Sarcoidosis.
Hypertrophic cardiomyopathy, except when due to an apical aneurysm.
Unstable angina.
Active myocardial ischemia.
Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.
Any percutaneous coronary intervention within 2 months (60 days) prior to the ablation procedure.
Any cardiac surgery within 3 months (90 days) prior to the ablation procedure.
Left ventricular ejection fraction (LVEF) \<15%.
NYHA Class IV heart failure.
Decompensated heart failure.
Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).
Ventricular assist device (VAD) implanted, planned or required for the procedure.
Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.
Presence of prosthetic valve in the aortic or mitral valve.
Patients with advanced COPD (on home oxygen).
Presence of intracardiac thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.
Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.
Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.
Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count \<80,000).
Contraindication to anticoagulation.
End-stage renal disease (requiring dialysis).
Acute illness, active infection, or sepsis.
Life expectancy less than 12 months.
Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.
Body mass index \>45 kg/m2.
Known ongoing drug or alcohol dependency.
Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).
Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Austin?

Yes, this clinical trial (NCT06703489) has an active research site in Austin, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ventricular Tachycardia (VT) Treatment Options in Austin, TX

If you're searching for ventricular tachycardia (vt) treatment options in Austin, TX, this clinical trial (NCT06703489) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Austin research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ventricular tachycardia (vt) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ventricular tachycardia (vt) clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Austin, TX

See all interstitial cystitis clinical trials recruiting in Austin — not just this study.

Browse Interstitial Cystitis Trials in Austin →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Austin?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Austin, TX